References
- Ahokas RA, Mabie WC, Sibai BM, Anderson GD. Labetalol does not decrease placental perfusion in the hypertensive term-pregnant rat. Am J Obstet Gynecol 1989; 160: 480–4
- Brinkman CR. Experimental renal hypertension in pregnant sheep: II. Response to one-kidney model. Am J Obstet Gynecol 1981; 141: 895–904
- Clark KE, Irion GL, Mack CE. Differential responses of uterine and umbilical vasculatures to angiotensin II and norepinephrine. Am J Physiol 1990; 259: H197–H203
- Dilts PV, Brinkman CR, Kirschbaum TH, Assali NS. Uterine and systemic hemodynamic interrelationships and their response to hypoxia. Am J Obstet Gynecol 1969; 103: 138–57
- Farmer JB, Kennedy I., Levy GP, Marshall RJ. Pharmacology of AH 5158; a drug which blocks both α- and β-adrenoceptors. Br J Pharmacol 1972; 45: 660–75
- Ginsburg J., Duncan SL. Peripheral circulation in hypertensive pregnancy. Cardiovasc Res 1967; 1: 356–61
- Jouppila P., Kirkinen P., Koivula A., Ylikorkala O. Labetalol does not alter the placental and fetal blood flow or maternal prostanoids in pre-eclampsia. Br J Obstet Gynaecol 1986; 93: 543–7
- Koch G. Acute hemodynamic effects of an alpha- and beta-receptor blocking agent (AH 5158) on the systemic and pulmonary circulation at rest and during exercise in hypertensive patients. Am Heart J 1977; 93: 585–91
- Ladner C., Brinkman CR, Weston P., Assali NS. Dynamics of uterine circulation in pregnant and nonpregnant sheep. Am J Physiol 1970; 218: 257–63
- Lardoux H., Gerard J., Blazquez G., Chouty F., Flouvat B. Hypertension in pregnancy: evaluation of two beta blockers atenolol and labetalol. Eur Heart J 1983; 4: 35–40, (Suppl G
- Lunell NO, Nylund L., Lewander R., Sarby B. Acute effect of an antihypertensive drug, labetalol, on uteroplacental blood flow. Br J Obstet Gynaecol 1982; 89: 640–4
- Lunell N-O, Hjemdahl P., Fredholm BB, Nisell H., Persson B., Wager J. Circulatory and metabolic effects of a combined α-and β-adrenoceptor blocker (labetalol) in hypertension of pregnancy. Br J Clin Pharmacol 1981; 12: 345–8
- MacPherson M., Broughton Pipkin F., Rutter N. The effect of maternal labetalol on the newborn infant. Br J Obstet Gynaecol 1986; 93: 539–42
- Michael CA. The evaluation of labetalol in the treatment of hypertension complicating pregnancy. Br J Clin Pharmacol 1982; 13: 127S–31S
- Moutquin JM, Rainville C., Giroux L., Raynauld P., Amyot G., Bilodeau R., Pelland N. A prospective study of blood pressure in pregnancy: Prediction of pre-eclampsia. Am J Obstet Gynecol 1985; 151: 191–6
- Plouin P-F, Breart G., Maillard F., Papiernik E., Relier J-P. Comparison of antihypertensive efficacy and perinatal safety of labetalol and methyldopa in the treatment of hypertension in pregnancy: a randomized controlled trial. Br J Obstet Gynaecol 1988; 95: 868–76
- Rurak D., Selke P., Fisher M., Taylor S., Wittmann B. Fetal oxygen extraction: Comparison of the human and sheep. Am J Obstet Gynecol 1987; 156: 360–366
- Riley AJ. Clinical pharmacology of labetalol in pregnancy. J Cardiovasc Pharmacol 1981; 3: S53–9, (Suppl 1
- Skillman CA, Plessinger MA, Woods JR, Clark KE. Effects of graded reductions in uteroplacental blood flow on the fetal lamb. Am J Physiol 1985; 249: H1098–105
- Talledo OE, Chesley LC, Zuspan FP. Renin-angiotensin system in normal and toxemic pregnancies. III. Differential sensitivity to angiotensin II and norepinephrine in toxemia of pregnancy. Am J Obstet Gynecol 1968; 100: 218–21